Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Reshoring Update: BMS Commits $2.3B to Houston Campus

10 August 2026 · By · Wire by Fusion42

Published

10 August 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at pharmaceuticalcommerce.com →

◆ Verified

Fusion42 · 25 August 2026 · Fusion42 review

Bristol Myers Squibb is investing $2.3 billion to build a modular, multi-product manufacturing campus in Houston as part of a broader $40 billion five-year U.S. reshoring investment in pharmaceutical manufacturing and R&D.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

Your pharmaceutical manufacturing options just got reshaped by BMS’s massive modular campus investment in Houston. Build your strategy now around flexible US sites that handle multiple drug types to stay ahead of growing onshore capacity and shifting supply chains.

◆ Coverage

2 sources · 10 Aug 2026

◆ Related on Wire

◆ Topics

Biotechreshoringpharma-manufacturingus-investmentmodular-factorybiotech